Ideal Medical Products accepts buyout deal
This article was originally published in The Gray Sheet
Executive Summary
Private equity fund HealthpointCapital acquires Paris-based Ideal Medical Products, the principal shareholder of spinal implant developer Scient'X. The two-step deal calls for the payment of $62 million to acquire the privately held Ideal Medical shares controlled by the Carli family, followed by initiation of a tender offer for the publicly held, minority interest in the company at $31.81 per share. Spinal fusion device maker Alphatec had sought to buy Scient'X in 2006 for $180 million, but the deal was later scuttled in favor of a licensing deal for Scient'X flagship dynamic stabilization product portfolio. HealthpointCapital, which also is Alphatec's principal stockholder, notes that this deal "will allow our firm to directly invest in and grow Scient'X" (1"The Gray Sheet" Jan. 29, 2007, p. 15)
You may also be interested in...
Alphatec Opts For Scient’X Spine Stabilization Device After Acquisition Fails
Spinal fusion device maker Alphatec Holding gains the rights to manufacture and distribute Scient'X's flagship dynamic stabilization product portfolio in the United States under one of three licensing agreements signed in lieu of a planned acquisition
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.